NEUROCRINE BIOSCIENCES INC — Form 10-Q
Filed November 2, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Effective September 28, 2026, Neurocrine reappointed Dr. Eiry W. Roberts as Chief Medical Officer under a new employment agreement (previously Strategic Advisor since May 2025). Compensation: $825,000 annual base salary, 60% target bonus, plus three equity grants totaling ~$1.25M (stock options $625k, RSUs $250k, performance RSUs $375k). Grants vest over 4 years; options vest monthly over 48 months. Roberts reports to CEO Kyle Gano and is subject to standard clawback policies and 409A compliance provisions.
Why this rating
CMO role change is routine exec reclassification. $1.08M total annual comp (~0.011% of $9.5B market cap) is immaterial. No material business impact disclosed.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.